It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Interview with John M. Barry author of "The Great Influenza: The Epic Story of the Deadliest Plague in History" recorded February 9, 2005 in Seattle
MADRID, May 23 (Xinhua) -- More than 500 servicemen from the Hoyo de Manzanres Base near Madrid have been quarantined when 11 of them were found to be infected with the A/H1N1 flu virus, Spanish First Deputy Prime Minister Maria Fernandez de la Vega said on Friday.
Sixty-one other servicemen are under observation, according to a report by the Spanish health ministry.
The Secretary General of the Spanish Health Ministry, Jose Martinez Olmos, said the 11 servicemen had not visited Mexico recently and an investigation into the origin of the infection was underway.
Woman in her 50s is NYC's 2nd swine flu death
13 mins ago
NEW YORK – A woman in her 50s is New York City's second confirmed death linked to swine flu.
A spokeswoman for the city's Department of Health and Mental Hygiene says the woman died over the weekend and had underlying health conditions.
Assistant public school principal Mitchell Wiener (WEE'-ner) became the city's first death from the virus a week ago.
The city's first outbreak of swine flu occurred about a month ago, when more than 1,000 teenagers at a Catholic high school in Queens began falling ill following the return of several students from vacations in Mexico, the epicenter of the outbreak.
SAN DIEGO, May 21, 2009 (GlobeNewswire via COMTEX) -- Vical Incorporated /quotes/comstock/15*!vicl/quotes/nls/vicl (VICL 2.13, -0.12, -5.33%) announced today that in the two weeks since launching its program to develop a vaccine against H1N1 influenza (swine flu), the company has completed development of a prototype H1 vaccine, produced an initial supply of research-grade material, and initiated immunogenicity testing in animals. Assuming a successful outcome of this testing and a commitment for program-specific external funding, the company is ready to advance directly to large-scale cGMP manufacturing of vaccine for human clinical trials to be conducted by the U.S. Navy.
The company previously announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Center (NMRC), a biomedical research organization within the U.S. Navy, to advance into clinical testing as quickly as possible a Vaxfectin(r)-formulated H1 DNA vaccine. Vical and the NMRC are actively pursuing funding to support the program.
Too early to make many predictions, and local conditions vary wildly. At least this captures what we know.